Noninvasive proton beam therapy may help treat dangerous heart rhythm disorder: Study

Mayo Clinic researchers report that a highly targeted, noninvasive form of radiation therapy reduced episodes of a life-threatening heart rhythm disorder by nearly 80% in a first-in-human early feasibility study of patients with few remaining treatment options.

The findings, presented as late-breaking research at the Heart Rhythm Society conference on April 26 and published in the Heart Rhythm Journal, suggest proton beam therapy could offer a new approach for patients with ventricular tachycardia (VT), a dangerous, fast heart rhythm disorder that can lead to sudden cardiac death.

Researchers treated seven patients with advanced heart disease and difficult-to-treat VT who had not responded to prior catheter ablations and antiarrhythmic medications. Patients experienced a 79% reduction in VT episodes, decreasing from an average of 7.2 episodes per month before treatment to 1.5 afterward. The therapy was delivered in a single, noninvasive session with proton beams directed to the area of the heart causing VT.

There were no serious treatment-related side effects during follow-up of up to two years, and key measures of heart function remained largely stable.

"These patients with challenging arrhythmias often run out of treatment options," says Konstantinos Siontis, M.D., a Mayo Clinic cardiologist and heart rhythm specialist who is the study's lead investigator. "We're seeing that a completely noninvasive approach may significantly reduce episodes of ventricular tachycardia."

Cardiac radioablation is an emerging treatment that uses radiation to target the areas of the heart responsible for abnormal electrical signals causing VT. This study builds on extensive previous preclinical Mayo Clinic research evaluating the use of proton beam therapy for this purpose. Compared with conventional radiation approaches, proton therapy allows for more precise targeting, helping limit radiation exposure to nearby healthy heart tissue and surrounding organs.

"These findings are encouraging because they demonstrate that we can precisely target the heart tissue responsible for VT while minimizing radiation exposure to the rest of the heart," says Kenneth Merrell, M.D., a radiation oncologist at Mayo Clinic and study co-author. "This is an early, first-in-human experience using proton therapy for cardiac radioablation."

Patients in the study had advanced heart failure and remained at risk for complications related to their underlying disease. Some participants died or required a heart transplant during follow-up due to their advanced heart disease.

"Our results support continued investigation of proton beam therapy in larger clinical trials," Dr. Siontis says. "The goal is to better understand which patients may benefit most and to confirm long-term safety and effectiveness."

Reference:

Konstantinos C. Siontis, Kenneth W. Merrell, Amanda J. Deisher, Dean A. Shumway, Maryam E. Rettmann, Suraj Kapa, Gurukripa N. Kowlgi, Samuel J. Asirvatham, Eric M. Welch, Jon Kruse, Robert L. Foote, Douglas L. Packer, Early Feasibility Study of Catheter-Free Cardiac Radioablation with Proton Beams for Refractory Ventricular Tachycardia, Heart Rhythm,2026, https://doi.org/10.1016/j.hrthm.2026.04.021.